The use of oral molnupiravir treatment within 5 days of COVID-19 symptom onset led to at least 50 percent reduction in the risk of hospitalisation and mortality among unvaccinated patients. A study conducted by the MOVe-OUT group, which was supported by Merck Sharp and Dohme, covered 1,433 participants with at least one risk factor with a median age of 42 for 5 days and found that there were no adverse events. The researchers said that among the cohort, there was one death reported in the molnupiravir group and 9 in the placebo group, all of which were considered to be COVID-19-related.